Thus, NRF2 activation in cancer cells reduces immune cell infiltration into tumors and the elevation of circulating immune cells in tumor-bearing mice by exploiting a distinct regulatory pathway from the MDSC pathways. The gene discussed is NFE2L2; the disease is neoplasm.